Literature DB >> 31365052

Increased translation as a novel pathogenic mechanism in Huntington's disease.

Jordi Creus-Muncunill1,2,3, Raquel Badillos-Rodríguez1,2,3, Marta Garcia-Forn1,2,3, Mercè Masana1,2,3, Gerardo Garcia-Díaz Barriga1,2,3, Anna Guisado-Corcoll1,2,3, Jordi Alberch1,2,3, Cristina Malagelada1, José M Delgado-García4, Agnès Gruart4, Esther Pérez-Navarro1,2,3.   

Abstract

Huntington's disease is a neurodegenerative disorder caused by a CAG repeat expansion in exon 1 of the huntingtin gene. Striatal projection neurons are mainly affected, leading to motor symptoms, but molecular mechanisms involved in their vulnerability are not fully characterized. Here, we show that eIF4E binding protein (4E-BP), a protein that inhibits translation, is inactivated in Huntington's disease striatum by increased phosphorylation. Accordingly, we detected aberrant de novo protein synthesis. Proteomic characterization indicates that translation specifically affects sets of proteins as we observed upregulation of ribosomal and oxidative phosphorylation proteins and downregulation of proteins related to neuronal structure and function. Interestingly, treatment with the translation inhibitor 4EGI-1 prevented R6/1 mice motor deficits, although corticostriatal long-term depression was not markedly changed in behaving animals. At the molecular level, injection of 4EGI-1 normalized protein synthesis and ribosomal content in R6/1 mouse striatum. In conclusion, our results indicate that dysregulation of protein synthesis is involved in mutant huntingtin-induced striatal neuron dysfunction.
© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  4E-BP1; 4EGI-1; long-term depression; ribosomal proteins; striatum

Mesh:

Substances:

Year:  2019        PMID: 31365052     DOI: 10.1093/brain/awz230

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  12 in total

1.  Huntington's disease brain-derived small RNAs recapitulate associated neuropathology in mice.

Authors:  Jordi Creus-Muncunill; Anna Guisado-Corcoll; Veronica Venturi; Lorena Pantano; Georgia Escaramís; Marta García de Herreros; Maria Solaguren-Beascoa; Ana Gámez-Valero; Cristina Navarrete; Mercè Masana; Franc Llorens; Daniela Diaz-Lucena; Esther Pérez-Navarro; Eulàlia Martí
Journal:  Acta Neuropathol       Date:  2021-02-06       Impact factor: 17.088

2.  Altered m6A RNA methylation contributes to hippocampal memory deficits in Huntington's disease mice.

Authors:  Silvia Ginés; Verónica Brito; Anika Pupak; Ankita Singh; Anna Sancho-Balsells; Rafael Alcalá-Vida; Marc Espina; Albert Giralt; Eulàlia Martí; Ulf Andersson Vang Ørom
Journal:  Cell Mol Life Sci       Date:  2022-07-11       Impact factor: 9.207

Review 3.  The science of puromycin: From studies of ribosome function to applications in biotechnology.

Authors:  Ranen Aviner
Journal:  Comput Struct Biotechnol J       Date:  2020-04-24       Impact factor: 7.271

4.  Mutant Huntingtin stalls ribosomes and represses protein synthesis in a cellular model of Huntington disease.

Authors:  Mehdi Eshraghi; Pabalu P Karunadharma; Juliana Blin; Neelam Shahani; Emiliano P Ricci; Audrey Michel; Nicolai T Urban; Nicole Galli; Manish Sharma; Uri Nimrod Ramírez-Jarquín; Katie Florescu; Jennifer Hernandez; Srinivasa Subramaniam
Journal:  Nat Commun       Date:  2021-03-05       Impact factor: 14.919

Review 5.  Eukaryotic ribosome quality control system: a potential therapeutic target for human diseases.

Authors:  Peng-Yue Zhao; Ren-Qi Yao; Zi-Cheng Zhang; Sheng-Yu Zhu; Yu-Xuan Li; Chao Ren; Xiao-Hui Du; Yong-Ming Yao
Journal:  Int J Biol Sci       Date:  2022-03-14       Impact factor: 6.580

Review 6.  Mammalian/mechanistic target of rapamycin (mTOR) complexes in neurodegeneration.

Authors:  Henry Querfurth; Han-Kyu Lee
Journal:  Mol Neurodegener       Date:  2021-07-02       Impact factor: 14.195

7.  Synaptic RTP801 contributes to motor-learning dysfunction in Huntington's disease.

Authors:  Núria Martín-Flores; Leticia Pérez-Sisqués; Jordi Creus-Muncunill; Mercè Masana; Sílvia Ginés; Jordi Alberch; Esther Pérez-Navarro; Cristina Malagelada
Journal:  Cell Death Dis       Date:  2020-07-30       Impact factor: 8.469

8.  M2 cortex-dorsolateral striatum stimulation reverses motor symptoms and synaptic deficits in Huntington's disease.

Authors:  Sara Fernández-García; Sara Conde-Berriozabal; Esther García-García; Clara Gort-Paniello; David Bernal-Casas; Gerardo García-Díaz Barriga; Javier López-Gil; Emma Muñoz-Moreno; Guadalupe Soria; Leticia Campa; Francesc Artigas; Manuel José Rodríguez; Jordi Alberch; Mercè Masana
Journal:  Elife       Date:  2020-10-05       Impact factor: 8.140

Review 9.  RNA Localization and Local Translation in Glia in Neurological and Neurodegenerative Diseases: Lessons from Neurons.

Authors:  Maite Blanco-Urrejola; Adhara Gaminde-Blasco; María Gamarra; Aida de la Cruz; Elena Vecino; Elena Alberdi; Jimena Baleriola
Journal:  Cells       Date:  2021-03-12       Impact factor: 6.600

10.  Neuron type-specific increase in lamin B1 contributes to nuclear dysfunction in Huntington's disease.

Authors:  Rafael Alcalá-Vida; Marta Garcia-Forn; Carla Castany-Pladevall; Jordi Creus-Muncunill; Yoko Ito; Enrique Blanco; Arantxa Golbano; Kilian Crespí-Vázquez; Aled Parry; Guy Slater; Shamith Samarajiwa; Sandra Peiró; Luciano Di Croce; Masashi Narita; Esther Pérez-Navarro
Journal:  EMBO Mol Med       Date:  2020-12-28       Impact factor: 14.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.